4,5-dipentyl-1H-imidazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4,5-dipentyl-1H-imidazole
• 英文别名: 4,5-Dipentyl-1H-imidazol；4,5-dipentyl-1H-imidazole
• 化学式: C₁₃H₂₄N₂
• 分子量: 208.347
• InChiKey: BVYIRHNTUGXQPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  15
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  7-羟基-6-十二烷酮 、 甲脒 生成 4,5-dipentyl-1H-imidazole
  参考文献：
  名称：

  Bredereck et al., Angewandte Chemie, 1959, vol. 71, p. 753,757

  摘要：

  DOI：

文献信息

• [EN] POLYSUBSTITUTED PYRROLES HAVING MICROTUBULE-DISRUPTING, CYTOTOXIC AND ANTITUMOR ACTIVITIES AND METHDS OF USE THEREOF<br/>[FR] PYRROLES POLYSUBSTITUÉS AYANT DES ACTIVITÉS DE RUPTURE DE MICROTUBULES, CYTOTOXIQUES ET ANTITUMORALES ET MÉTHODES LES UTILISANT
  申请人：KELLOGG GLEN E

  公开号：WO2015039073A1

  公开（公告）日：2015-03-19

  The present invention provides polysubstituted pyrrole compounds, pharmaceutically effective salts, prodrugs, solvates and hydrates thereof, having antimitotic, antiproliferative and cytotoxic activity, activity against cells expressing the drug efflux protein, P-glycoprotein, or cells expressing the β-ΙΙΙ isotype of tubulin and antitumor activity. Also provided are methods of utilizing these compounds for inhibiting the proliferation of cancer cells as well as their medical use, in particular for treating cancer, including drug resistant cancer.

  本发明提供了多取代吡咯化合物，药效盐、前药、溶剂合物和水合物，具有抗有丝分裂、抗增殖和细胞毒活性，对表达药物外流蛋白P-糖蛋白的细胞、或表达β-ΙΙΙ微管蛋白亚型的细胞具有活性，并具有抗肿瘤活性。还提供了利用这些化合物抑制癌细胞增殖的方法，以及它们的医疗用途，特别是用于治疗癌症，包括耐药性癌症。
• CB1 Antagonists or inverse agonists as therapeutical agents for the treatment of inflammation involving gene expression
  申请人：LABORATORIOS DEL DR. ESTEVE, S.A.

  公开号：EP1752149A1

  公开（公告）日：2007-02-14

  The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animal.

  本发明涉及替代吡唑啉化合物，其制备方法，包含这些化合物的药物，以及它们用于制备用于治疗人类和动物的药物的用途。
• Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine
  申请人：Deng Xiaohu

  公开号：US20070027319A1

  公开（公告）日：2007-02-01

  This invention relates to methods of making pyrimidinyl-substituted imidazole compounds by sequential substitution of the 4- and 2-chloro groups of 2,4-dichloropyrimidine, nucleophilic substitution to form pyrimidinylalkyne derivatives, oxidation to the corresponding 1,2-diketones, and cyclocondensation reactions.

  这项发明涉及通过对2,4-二氯嘧啶的4-和2-氯基进行顺序取代，亲核取代形成嘧啶基炔衍生物，氧化成对应的1,2-二酮，以及环缩合反应制备嘧啶基取代咪唑化合物的方法。
• [EN] TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS<br/>[FR] COMPOSÉS HÉTÉROBIFONCTIONNELS TRICYCLIQUES POUR LA DÉGRADATION DE PROTÉINES CIBLÉES
  申请人：C4 THERAPEUTICS INC

  公开号：WO2022081928A1

  公开（公告）日：2022-04-21

  Heterobifunctional compounds for targeted protein degradation that include a tricyclic cereblon binder linked to an appropriate protein targeting ligand to degrade a targeted disease-mediating protein of interest are provided.

  本发明提供了用于靶向蛋白降解的异双功能化合物，其中包括一个三环Cereblon结合剂，连接到一个适当的蛋白靶向配体，以降解感兴趣的靶向疾病介导蛋白质。
• [EN] 4,5-DIARYLIMIDAZOLE DERIVATIVES AS HDAC INHIBITORS<br/>[FR] DÉRIVÉS DE 4,5-DIARYLIMIDAZOLE COMME INHIBITEURS DE HDAC
  申请人：CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN

  公开号：WO2016008836A1

  公开（公告）日：2016-01-21

  The present invention relates to a 4,5-diarylimidazole derivative of formulae (I), (II) or (III): or a pharmaceutically acceptable salt thereof, wherein the 4,5-diarylimidazole derivative has a hydroxamic acid residue at a first aryl ring and a residue R1 at a second aryl ring; and wherein R1 is hydrogen, a halogen atom or an unsubstituted or substituted alkoxy group; R2 is independently selected from an unsubstituted or substituted alkyl, alkoxy or alkene group; M is a metal atom; L is a halogen atom, an unsubstituted or substituted phosphane, sulfane, arene or alkene group or a 4,5-diarylimidazole-derivative of formula (I); and n is an integer of from 1 to 5.

  本发明涉及一种式(I)、(II)或(III)的4,5-二芳基咪唑衍生物或其药学上可接受的盐，其中4,5-二芳基咪唑衍生物在第一个芳基环上具有一个羟肟酸残基，在第二个芳基环上具有残基R1；其中R1是氢、卤素原子或未取代或取代的烷氧基团；R2是独立选择的未取代或取代的烷基、烷氧基或烯基团；M是金属原子；L是卤素原子、未取代或取代的膦、硫醇、芳烃或烯基团或式(I)的4,5-二芳基咪唑衍生物；n是1至5的整数。